Biofunctionalization with a TGF-beta1 Inhibitor peptide in the osseointegration of synthetic bone grafts: an in vivo study in beagle dogs.

Cirera A. et al. 2019. Materials (Basel);12(19). pii: E3168.

The pre-clinical study determined the osseointegration of two formulations of maxresorb®, untreated or combined with a TGF-β1 inhibitor peptide in dental alveoli. TGF-β1 is described to be a mediator in cellular responses, such as fibrotic responses with increased expression levels in failed implant placements.

Material and Methods:
Two formulations of maxresorb® were implanted in 6 beagle dogs in a hemimandible model following tooth extraction of the second and third premolar. Histological and histomorphometrical analysis were performed 2, 4, and 8 weeks following surgery with regard to new bone formation.

Healing was uneventful and peri-implant mucosa appeared healthy. Bone augmentation with maxresorb® showed good osseointegration. The combination with the TGF-β1 inhibitor peptide presented even better results with higher osseous tissue apposition. Ultramicroscopic analysis revealed that the combination of maxresorb® with TGF-β1 inhibitor peptide may shorten the healing time of dental biomaterials.

A. Cirera


Leave A Comment

Related Posts

REVIEW | Tel Aviv

bone & tissue days Tel Aviv 2018

Tags: , , , , , , , , , , , , , , , , , , , , , |